Your browser does not support SVG.
  • HOME
  • PIPELINE
  • LEADERSHIP
    Management TeamBoard of Directors
  • DISEASES
    Acne vulgarisAtopic dermatitisHyperhidrosisPsoriasisVitiligo
  • NEWS
  • CAREERS
  • CONTACT

December 2016

December 2016

December 21, 2016

Licensing of Topical Cerdulatinib ...

Read More

Recent Posts

  • Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo

  • Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis

  • Dermavant Sciences Appoints Timothy S. Nelson and Kenneth E. Ludlum to Board of Directors

  • Dermavant Sciences Announces Appointment of Cyril Allouche as Chief Financial Officer and Provides Recent Corporate Update

  • Dermavant Sciences to Present Data on Tapinarof for Psoriasis and Atopic Dermatitis at the 2019 American Academy of Dermatology Annual Meeting

Archives

  • December 2019
  • June 2019
  • May 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • April 2018
  • September 2017
  • July 2017
  • December 2016
  • November 2015

Categories

  • Dermavant Sciences
  • News
  • RVT-201
  • RVT-501
  • RVT-502
  • RVT-504
  • Tapinarof
  • Home
  • Pipeline
  • Leadership
    Management TeamBoard of Directors
  • Diseases
    Acne vulgarisAtopic dermatitisHyperhidrosisPsoriasisVitiligo
  • News
  • Careers
  • Contact

Copyright © 2019 Dermavant Sciences, Inc. All rights reserved.
Privacy Policy    |   Terms of Use